ArticleDiagnostic and interventional radiology (Ankara, Turkey)2026
Association between magnetic resonance imaging-based prostatic tissue morphology and changes in International Prostate Symptom Score and maximum urinary flow rate after prostatic artery embolization.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate whether baseline multiparametric magnetic resonance imaging (mpMRI)-defined prostate morphological phenotypes are associated with changes in the International Prostate Symptom Score (ΔIPSS) and maximum urinary flow rate (ΔQmax) following prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).
methodsThis retrospective single-center study included patients who underwent technically successful PAE with preprocedural mpMRI performed within 8 weeks of intervention. Prostate morphology was classified as glandular-dominant, stromal-dominant, or mixed phenotype based on the predominant nodule signal characteristics on T2-weighted imaging (T2WI), with supplemental assessment using diffusion-weighted and contrast-enhanced sequences when available. Symptomatic and functional outcomes-ΔIPSS and ΔQmax-were assessed at 3, 6, 12, and 24 months post-procedure. Associations between morphology and outcomes were evaluated using multivariable regression and subgroup analysis.
resultsA total of 152 patients (mean age, 70.0 ± 9.9 years) who underwent technically successful PAE were included in the study, all of whom had preprocedural MRI performed within 8 weeks prior to the intervention. All MRI-defined morphological phenotypes demonstrated improvements in the Qmax and IPSS after PAE. The glandular-dominant phenotype exhibited the most pronounced and earliest response, with peak improvements at 6 months (ΔQmax: 10.45 mL/s; ΔIPSS: 14.11 points) and sustained benefits through 24 months (ΔQmax: 8.78 mL/s; ΔIPSS: 13.04 points). Stromal-dominant and mixed phenotypes showed smaller, delayed improvements, typically peaking at 12 months. Morphology-related phenotype differences remained statistically significant at 24 months in unadjusted comparisons, particularly between glandular and stromal phenotypes, although ΔIPSS differences were attenuated in multivariable models (24-month β: 0.104,
conclusionBaseline MRI-defined prostate morphology, assessed primarily on T2WIs, was significantly associated with clinical outcomes after PAE; glandular-dominant morphology was linked to larger and more sustained improvements in both the Qmax and IPSS. Therefore, MRI-based phenotypes offer a practical imaging biomarker for patient stratification, warranting prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.